Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment
- PMID: 18383889
Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment
Abstract
Background: The effectiveness of photodynamic therapy (PDT) for ablation of high grade dysplasia (HGD) in Barrett's esophagus (BE) is typically reported histologically. Following successful PDT, Barrett's mucosa is replaced with neosquamous mucosa. The objective of this study was to compare the expression of p53 protein in neosquamous mucosa as compared to that in HGD samples not treated with PDT.
Patients and methods: The patients were divided into two groups. Group I patients (n = 12) had been treated with PDT for HGD and provided 23 biopsy samples of neosquamous mucosa. Group II patients (n = 10) had not received any ablative therapies for BE and provided 14 HGD samples. The immunohistochemical (IHC) staining for p53 protein was performed using mouse anti-human monoclonal antibody DO-1. The degree of p53 protein expression in the cell nuclei was scored using an established IHC scoring system (0 for negative samples and range of 2 to 8 for positive samples).
Results: The HGD samples showed diffuse strong p53 staining. The median IHC score for HGD was 7.0. The median IHC score for neosquamous mucosa following PDT was 4.0, with positive scores indicating weak staining in the basal layer of the neosquamous samples. There was significantly lower p53 expression in the neosquamous samples compared to that in the HGD samples (p < 0.001).
Conclusion: Significantly lower p53 protein expression was detected in neosquamous mucosa of patients who had received PDT for HGD, suggesting a decreased risk for neoplastic progression after treatment.
Similar articles
-
Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.Eur J Cardiothorac Surg. 2006 Jan;29(1):30-4. doi: 10.1016/j.ejcts.2005.10.033. Epub 2005 Dec 6. Eur J Cardiothorac Surg. 2006. PMID: 16337389
-
Porfimer sodium photodynamic therapy for management of Barrett's esophagus with high-grade dysplasia.Lasers Surg Med. 2006 Jun;38(5):390-5. doi: 10.1002/lsm.20367. Lasers Surg Med. 2006. PMID: 16788927
-
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial.Gastrointest Endosc. 2005 Oct;62(4):488-98. doi: 10.1016/j.gie.2005.06.047. Gastrointest Endosc. 2005. PMID: 16185958 Clinical Trial.
-
Laser ablation therapies for Barrett's esophagus.Semin Thorac Cardiovasc Surg. 2005 Winter;17(4):313-9. doi: 10.1053/j.semtcvs.2005.10.004. Semin Thorac Cardiovasc Surg. 2005. PMID: 16428037 Review.
-
Clinical use of p53 in Barrett's esophagus.Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1243-9. doi: 10.1158/1055-9965.EPI-06-0010. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16835318 Review.
Cited by
-
Treatment for Barrett's oesophagus.Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD004060. doi: 10.1002/14651858.CD004060.pub2. Cochrane Database Syst Rev. 2010. Retraction in: Cochrane Database Syst Rev. 2021 Mar 4;3:CD004060. doi: 10.1002/14651858.CD004060.pub3. PMID: 20091557 Free PMC article. Retracted.
-
Mucosal ablation of Barrett esophagus.Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):393-401. doi: 10.1038/nrgastro.2009.90. Epub 2009 Jun 2. Nat Rev Gastroenterol Hepatol. 2009. PMID: 19488071 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous